RYTM_January2026v_jpm.pdf

1、 Rhythm Pharmaceuticals,Inc.All rights reserved.Rhythm PharmaceuticalsCorporate PresentationJanuary 2026 2This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.All statements contained in

2、 this presentation that do not relate to matters of historical fact should be considered forward-looking statements,including without limitation statements regarding our preliminary,unaudited revenues for the fourth quarter and full year 2025;sufficiency of our cash and cash equivalents;the safety,e

3、fficacy,potential benefits of,and clinical design or progress of any of our products or product candidates at any dosage or in any indication,including,setmelanotide,bivamelagon,and RM-718;the potential use of setmelanotide in patients with acquired hypothalamic obesity;our expectations surrounding

4、potential regulatory submissions,progress,or approvals and timing thereof for any of our product candidates;the estimated market size and addressable population for our drug products,including setmelanotide for the treatment of hypothalamic obesity;the future announcement of data from our ongoing cl

5、inical trials,including the Japanese cohort of our Phase 3 trial evaluating setmelanotide for patients with acquired hypothalamic obesity,the substudy evaluating setmelanotide for patients with congenital hypothalamic obesity,the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused M

6、C4R pathway diseases;Part C of the Phase 1 trial evaluating RM-718,and the open-label Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome;the ongoing enrollment in our clinical trials;and the timing of any of the foregoing.Statements using words such as“expect”,“anticipate”